Lastly, and particularly in relation to AML with RUNX1::RUNXT1, although some reports suggest that cases with fewer than 10% blasts (and thus previously classified as MDS) may progress rapidly to AML (defined in earlier classifications as exceeding 30% blasts), the number of patients studied remains very limited [25, 26, 27, 28]. The gene discussed is RUNX1; the disease is acute myeloid leukemia.